News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BAC B.V. Collaborates in Providing Custom CaptureSelect(R) Affinity Ligands for Bristol-Myers Squibb Company (BMY)'s Adnectin(TM) Biotherapeutics


8/16/2011 9:03:53 AM

NAARDEN, The Netherlands--(BUSINESS WIRE)--BAC BV, the leading provider of antibody based affinity purification technology, has announced a collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to generate CaptureSelect® affinity ligands for applications in the purification and analysis of a proprietary type of targeted biologic, called Adnectins™. Derived from human fibronectin, Adnectins are engineered using Bristol-Myers Squibb’s proprietary PROfusion™ technology to either block or stimulate the action of specific targets across a broad range of therapeutic areas.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES